Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
17,688,582
-
Share change
-
+2,575,704
-
Total reported value
-
$273,807,295
-
Price per share
-
$15.48
-
Number of holders
-
73
-
Value change
-
+$42,268,055
-
Number of buys
-
43
-
Number of sells
-
29
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2020
As of 31 Mar 2020,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,688,582 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, Consonance Capital Management LP, HILLHOUSE CAPITAL ADVISORS, LTD., ArrowMark Colorado Holdings LLC, VANGUARD GROUP INC, BlackRock Inc., Sofinnova Investments, Inc., Vivo Capital, LLC, AMERIPRISE FINANCIAL INC, and CITADEL ADVISORS LLC.
This page lists
73
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.